Oculis AG(US:OCS) Globenewswire·2025-11-10 21:05Core Insights - Oculis Holding AG is advancing its position in ophthalmology and neuro-ophthalmology with a focus on innovative treatments addressing significant unmet medical needs [2][13] - The company has secured funding to support three pivotal trials for its product Privosegtor, targeting a market opportunity of approximately $7 billion in the U.S. [2][4] Financial Overview - As of September 30, 2025, Oculis reported cash, cash equivalents, and short-term investments totaling $182.2 million, with a recent capital raise increasing this amount to nearly $300 million [4][7] - Research and development expenses for Q3 2025 were $17.6 million, up from $15.0 million in Q3 2024, primarily due to increased product development activities [7] - The year-to-date net loss for the nine months ended September 30, 2025, was $89.7 million, compared to $64.8 million for the same period in 2024, driven by advancements in clinical development programs [7][12] Clinical Developments - Oculis is conducting Phase 3 trials for OCS-01 eye drops in diabetic macular edema (DME), with topline results expected in Q2 2026 [3][4] - The company is initiating the PIONEER program for Privosegtor, which includes three pivotal trials for acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION) [5][6] - Licaminlimab, a novel treatment for dry eye disease (DED), is set to enter a registrational trial in Q4 2025, following positive Phase 2 results [6][13] Market Opportunity - DME affects approximately 37 million people globally, representing a market opportunity of around $5 billion, highlighting the need for early intervention and effective treatments [6] - The potential market for Privosegtor in optic neuropathies is estimated at $7 billion in the U.S., with no current available therapies [2][4]